Digital-first experimental approach to optimise drug formulations
Merck and XtalPi Inc. collaborate on an AI-powered technology platform to predict the crystal morphologies of diabetic medication metformin HCl, validated by wet-lab experiments conducted with Merck’s expertise, in a ‘digital-first’ approach to drug development and optimisation.
Merck and Chinese pharmaceutical technology company XtalPi Inc. have published a collaborative study that leverages Merck’s wet-lab experimental capabilities with computational workflows provided by XtalPi for advanced drug development and manufacturing.
XtalPi delivers AI-powered pharmaceutical technology platforms to bring drug discovery and development solutions to the global pharmaceutical industry. Their collaboration with Merck utilised their morphology prediction platform, a crystal morphology engineering screening approach, in combination with Merck’s experimental capabilities to examine how different polymer additives affected the crystal habit of diabetic medication metformin HCl. The custom-made force fields brought by XtalPi’s platform successfully predicted the influence of these polymer additives. The predictions were validated by Merck’s wet-lab experiments.
XtalPi’s Chief Scientific Officer Peiyu Zhang commented that “By integrating XtalPi’s molecular dynamic predictions with Merck’s experimental validation, we have taken a step towards the rational engineering of desirable crystal habits. We hope to continue improving this ‘dry and wet’ lab method with leading industry experts like Merck in the production of novel therapeutics worldwide.”
Traditionally, undesirable crystal morphologies were investigated with disruptive and expensive lab methods such as milling and micronization. The ability of AI technology to provide molecular dynamics simulations demonstrates how AI-predictive technology platforms can be integrated into the drug development process for drug formulation optimisation and bring enhanced crystallization experiment designs.
Jan Gerit Brandenburg, Merck’s Head of Digital Chemistry, added: “Our collaboration with XtalPi is transforming pharmaceutical development. By seamlessly incorporating computer simulations with our experimental formulation expertise in a ‘digital-first’ approach, we are boosting [the] drug development processes and positively impacting patients’ lives.”
Source: Merck and XtalPi Collaboration Optimizes Drug Formulations with AI-Powered Techniques [Accessed April 17, 2023] https://www.prnewswire.com/news-releases/merck--xtalpi-collaboration-optimizes-drug-formulations-with-ai-powered-techniques-301797593.html
Discover new thinking at CPHI Barcelona
Innovations come in limitless forms. At CPHI Barcelona, you can hear from – and meet – experts who are driving their businesses forward with new thinking and new processes. Make connections, be inspired and get a fresh perspective on the road ahead.
Your CPHI Barcelona pass gives you access to all conference sessions, including Formulating the Future, as well as the chance to connect in-person with the global pharma supply chain from 24-26 October, at Fira Barcelona Gran Via. Browse the agenda and secure your pass today!
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance